Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.24%

Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the stock's slight decline of 0.24% suggests that investors may have been looking for more detailed guidance or revenue figures. The lack of revenue data and forward guidance could lead to uncertainty in the market moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$11.14	N/A	+30.31%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their product lineup and future prospects. However, they did not provide specific guidance for the upcoming quarters.

Management highlighted strong performance in key product areas.

They noted ongoing investments in research and development.

There was an emphasis on maintaining a strong pipeline for future growth.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.24%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.24%

Key numbers

Management commentary